ModeX Therapeutics, an OPKO Health Company
Clinical trials sponsored by ModeX Therapeutics, an OPKO Health Company, explained in plain language.
A biopharmaceutical company developing immunotherapies and vaccines, owned by OPKO Health.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody trial aims to block severe COVID-19 Results expected Sep 2027 (estimated)
-
New drug MDX2001 tested in 285 patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human testing
Disease control Recruiting nowThis study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug MDX2004 targets advanced tumors in early trial
Disease control Recruiting nowThis study tests a new drug, MDX2004, in 235 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must be 18 or older, in good daily function, and have …
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New antibody trial aims to block severe COVID-19
Prevention Recruiting nowThis early-stage study is testing an experimental antibody called MDX2301 to see if it can help prevent severe COVID-19 in healthy adults and those at higher risk. About 80 participants will receive either the antibody or a placebo, given as an injection or infusion. The main goa…
Phase 1 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC